Manchester score: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import Tags: mobile edit mobile web edit |
||
| Line 38: | Line 38: | ||
{{stub}} | {{stub}} | ||
{{No image}} | |||
Revision as of 03:41, 11 February 2025
Manchester Score is a clinical prediction rule for the diagnosis of gynecological cancer. It was developed by the researchers at the University of Manchester and is used to predict the likelihood of endometrial cancer in women presenting with postmenopausal bleeding (PMB).
Overview
The Manchester Score is calculated based on the following factors: age, body mass index (BMI), diabetes, hypertension, endometrial thickness, and bleeding pattern. Each factor is assigned a score, and the total score is used to predict the likelihood of endometrial cancer.
Calculation
The Manchester Score is calculated as follows:
- Age: 1 point for each year over 50
- BMI: 1 point for each unit over 25
- Diabetes: 20 points
- Hypertension: 20 points
- Endometrial thickness: 1 point for each millimeter
- Bleeding pattern: 20 points for PMB
The total score is then used to predict the likelihood of endometrial cancer. A score of less than 200 indicates a low risk, a score of 200-500 indicates a moderate risk, and a score of over 500 indicates a high risk.
Clinical Use
The Manchester Score is used in clinical practice to guide the management of women presenting with PMB. It helps to identify those at high risk of endometrial cancer who may benefit from further investigation and treatment.
Limitations
While the Manchester Score is a useful tool, it is not perfect. It does not take into account all possible risk factors for endometrial cancer, and it may not be accurate in all cases. Therefore, it should be used in conjunction with other clinical information and diagnostic tests.


